What is Envveno Medical Corporation's earnings per share (EPS)?

Envveno Medical Corporation (NVNO) reported diluted earnings per share of $-33.06 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Envveno Medical Corporation Financials

NVNO

Source SEC Filings (10-K/10-Q) Updated Mar 26, 2026 Currency USD FYE March

This page shows Envveno Medical Corporation (NVNO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Envveno Medical Corporation passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.80x

For every $1 of reported earnings, Envveno Medical Corporation generates $0.80 in operating cash flow (-$15.6M OCF vs -$19.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$20.8M

YoY+12.2%

Envveno Medical Corporation's EBITDA was -$20.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 12.2% from the prior year.

Net Income

-$19.5M

YoY+10.8%

Envveno Medical Corporation reported -$19.5M in net income in fiscal year 2025. This represents an increase of 10.8% from the prior year.

EPS (Diluted)

$-33.06

Envveno Medical Corporation earned $-33.06 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 2503.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$15.6M

YoY+7.7%

Envveno Medical Corporation generated -$15.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 7.7% from the prior year.

Cash & Debt

$3.1M

YoY+74.7%

5Y CAGR-20.0%

Envveno Medical Corporation held $3.1M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

655,521

Envveno Medical Corporation had 655,521 shares outstanding in fiscal year 2025. This represents a decrease of 96.3% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-71.8%

YoY-20.0pp

5Y CAGR+56.9pp

Envveno Medical Corporation's ROE was -71.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 20.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$10.0M

YoY-18.5%

5Y CAGR+18.6%

Envveno Medical Corporation invested $10.0M in research and development in fiscal year 2025. This represents a decrease of 18.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$5K

YoY-86.5%

5Y CAGR-51.2%

Envveno Medical Corporation invested $5K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 86.5% from the prior year.

NVNO Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$10.0M-18.5%	$12.2M-9.8%	$13.6M+37.0%	$9.9M+73.1%	$5.7M+34.7%	$4.3M
SG&A Expenses	$10.9M-5.7%	$11.6M-0.7%	$11.7M-22.4%	$15.0M+34.5%	$11.2M+128.7%	$4.9M
Operating Income	-$20.9M+12.3%	-$23.8M+5.6%	-$25.2M-1.2%	-$24.9M-47.6%	-$16.9M-84.9%	-$9.1M
Interest Expense	N/A	N/A	N/A	$161K+747.4%	$19K+408.2%	$4K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$19.5M+10.8%	-$21.8M+7.2%	-$23.5M+4.7%	-$24.7M-49.3%	-$16.5M-80.9%	-$9.1M
EPS (Diluted)	$-33.06	$-1.27+33.5%	$-1.91+13.2%	$-2.20	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.6M-10.6%	$2.9M+13.1%	$2.6M	N/A	$2.9M+1.2%	$2.8M-7.4%	$3.1M	N/A
SG&A Expenses	$2.3M-44.7%	$4.2M+73.5%	$2.4M	N/A	$3.3M+25.9%	$2.6M+7.3%	$2.5M	N/A
Operating Income	-$4.9M+30.7%	-$7.0M-42.3%	-$5.0M	N/A	-$6.2M-13.1%	-$5.5M+0.9%	-$5.5M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$4.5M+32.2%	-$6.7M-48.7%	-$4.5M	N/A	-$5.6M-13.8%	-$5.0M+0.7%	-$5.0M	N/A
EPS (Diluted)	$-0.23+30.3%	$-0.33-50.0%	$-0.22	N/A	$-0.35-12.9%	$-0.310.0%	$-0.31	N/A

NVNO Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$29.6M-34.2%	$45.0M-7.6%	$48.6M+16.7%	$41.7M-27.8%	$57.7M+447.5%	$10.5M
Current Assets	$28.8M-34.1%	$43.7M-6.8%	$46.9M+19.0%	$39.4M-28.4%	$55.0M+475.2%	$9.6M
Cash & Equivalents	$3.1M+74.7%	$1.8M-51.5%	$3.6M-20.5%	$4.6M-91.7%	$54.7M+486.3%	$9.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.4M-13.0%	$2.8M+14.8%	$2.4M-17.0%	$2.9M-11.0%	$3.3M-4.2%	$3.4M
Current Liabilities	$2.1M+1.3%	$2.1M+52.8%	$1.4M-10.4%	$1.5M-3.2%	$1.6M-50.4%	$3.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$27.1M-35.6%	$42.2M-8.7%	$46.2M+19.3%	$38.7M-28.8%	$54.4M+666.5%	$7.1M
Retained Earnings	-$171.3M-12.8%	-$151.9M-16.8%	-$130.0M-22.1%	-$106.5M-30.1%	-$81.9M-25.3%	-$65.3M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$32.4M-11.6%	$36.6M-9.9%	$40.6M-9.7%	$45.0M-10.8%	$50.4M+22.9%	$41.0M-8.6%	$44.8M-7.8%	$48.6M
Current Assets	$31.5M-11.5%	$35.6M-9.8%	$39.5M-9.7%	$43.7M-10.8%	$49.1M+24.1%	$39.5M-8.6%	$43.2M-7.8%	$46.9M
Cash & Equivalents	$1.5M-24.5%	$2.0M-30.4%	$2.9M+67.4%	$1.8M-90.2%	$17.9M+652.7%	$2.4M+2.9%	$2.3M-36.1%	$3.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.9M-17.5%	$3.5M+55.1%	$2.3M-18.8%	$2.8M-7.5%	$3.0M+17.2%	$2.6M+4.8%	$2.5M+1.0%	$2.4M
Current Liabilities	$2.4M-20.4%	$3.0M+81.5%	$1.7M-20.7%	$2.1M-6.0%	$2.2M+31.5%	$1.7M+14.0%	$1.5M+8.5%	$1.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$29.4M-10.9%	$33.1M-13.7%	$38.3M-9.1%	$42.2M-11.0%	$47.4M+23.3%	$38.4M-9.3%	$42.4M-8.3%	$46.2M
Retained Earnings	-$167.6M-2.8%	-$163.1M-4.3%	-$156.4M-3.0%	-$151.9M-4.3%	-$145.6M-4.0%	-$140.0M-3.7%	-$135.0M-3.8%	-$130.0M

NVNO Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$15.6M+7.5%	-$16.8M+10.7%	-$18.9M-20.7%	-$15.6M-31.8%	-$11.8M-54.3%	-$7.7M
Capital Expenditures	$5K-86.5%	$37K+12.1%	$33K-71.3%	$115K-68.8%	$368K+104.1%	$180K
Free Cash Flow	-$15.6M+7.7%	-$16.9M+10.7%	-$18.9M-20.1%	-$15.7M-28.8%	-$12.2M-55.5%	-$7.9M
Investing Cash Flow	$15.9M+1087.7%	$1.3M+117.0%	-$7.9M+77.2%	-$34.6M-9289.7%	-$368K-104.1%	-$180K
Financing Cash Flow	$1.0M-92.5%	$13.6M-47.1%	$25.8M	N/A	$57.6M+282.1%	$15.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$4.4M-18.2%	-$3.7M+7.5%	-$4.0M+21.3%	-$5.1M-19.4%	-$4.3M-9.4%	-$3.9M-10.1%	-$3.5M+28.6%	-$5.0M
Capital Expenditures	$0	N/A	N/A	$4K-55.6%	$9K-35.7%	$14K+40.0%	$10K+150.0%	$4K
Free Cash Flow	-$4.4M	N/A	N/A	-$5.1M-19.2%	-$4.3M-9.3%	-$3.9M-10.1%	-$3.6M+28.5%	-$5.0M
Investing Cash Flow	$3.7M+29.4%	$2.8M-45.7%	$5.2M+147.0%	-$11.1M-277.7%	$6.2M+56.6%	$4.0M+80.8%	$2.2M+109.9%	-$22.1M
Financing Cash Flow	N/A	N/A	N/A	$0-100.0%	$13.6M	$0-100.0%	$46K	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NVNO Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-71.8%-20.0pp	-51.7%-0.8pp	-50.9%+12.8pp	-63.7%-33.3pp	-30.4%+98.3pp	-128.7%
Return on Assets	-65.9%-17.3pp	-48.5%-0.2pp	-48.4%+10.9pp	-59.2%-30.6pp	-28.6%+58.0pp	-86.7%
Current Ratio	13.58-7.3	20.88-13.4	34.23+8.5	25.78-9.1	34.84+31.8	3.00
Debt-to-Equity	0.09+0.0	0.07+0.0	0.05-0.0	0.08+0.0	0.06-0.4	0.48
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-15.4%+4.8pp	-20.3%-8.5pp	-11.8%	N/A	-11.9%+1.0pp	-12.9%-1.1pp	-11.8%	N/A
Return on Assets	-14.0%+4.3pp	-18.3%-7.2pp	-11.1%	N/A	-11.2%+0.9pp	-12.1%-0.9pp	-11.1%	N/A
Current Ratio	13.12+1.3	11.81-12.0	23.77+2.9	20.88-1.1	22.01-1.3	23.33-5.8	29.08-5.1	34.23
Debt-to-Equity	0.100.0	0.11+0.0	0.060.0	0.070.0	0.060.0	0.070.0	0.060.0	0.05
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Intelligent Bio Solutions Inc INBS

$5.5M

Nexalin Tech NXL

$7.2M

Ainos Inc AIMD

$10.5M

ALLURION TECHNOLOGIES INC ALUR

$10.0M

Beyond Air Inc XAIR

$7.5M

Frequently Asked Questions

Is Envveno Medical Corporation profitable?

No, Envveno Medical Corporation (NVNO) reported a net income of -$19.5M in fiscal year 2025.

What is Envveno Medical Corporation's EBITDA?

Envveno Medical Corporation (NVNO) had EBITDA of -$20.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Envveno Medical Corporation's return on equity (ROE)?

Envveno Medical Corporation (NVNO) has a return on equity of -71.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Envveno Medical Corporation's free cash flow?

Envveno Medical Corporation (NVNO) generated -$15.6M in free cash flow during fiscal year 2025. This represents a 7.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Envveno Medical Corporation's operating cash flow?

Envveno Medical Corporation (NVNO) generated -$15.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Envveno Medical Corporation's total assets?

Envveno Medical Corporation (NVNO) had $29.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Envveno Medical Corporation's capital expenditures?

Envveno Medical Corporation (NVNO) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Envveno Medical Corporation spend on research and development?

Envveno Medical Corporation (NVNO) invested $10.0M in research and development during fiscal year 2025.

How many shares does Envveno Medical Corporation have outstanding?

Envveno Medical Corporation (NVNO) had 655,521 shares outstanding as of fiscal year 2025.

What is Envveno Medical Corporation's current ratio?

Envveno Medical Corporation (NVNO) had a current ratio of 13.58 as of fiscal year 2025, which is generally considered healthy.

What is Envveno Medical Corporation's debt-to-equity ratio?

Envveno Medical Corporation (NVNO) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Envveno Medical Corporation's return on assets (ROA)?

Envveno Medical Corporation (NVNO) had a return on assets of -65.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Envveno Medical Corporation's cash runway?

Based on fiscal year 2025 data, Envveno Medical Corporation (NVNO) had $3.1M in cash against an annual operating cash burn of $15.6M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Envveno Medical Corporation's Piotroski F-Score?

Envveno Medical Corporation (NVNO) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Envveno Medical Corporation's earnings high quality?

Envveno Medical Corporation (NVNO) has an earnings quality ratio of 0.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.